Lisa Licitra

1987–2025 年に発表

205
論文数
34,802
被引用数
88
h 指数
188
i10 指数

被引用数

Lisa Licitra の年別被引用数1988 年: 被引用 10 件1989 年: 被引用 6 件1990 年: 被引用 8 件1991 年: 被引用 11 件1992 年: 被引用 16 件1993 年: 被引用 5 件1994 年: 被引用 10 件1995 年: 被引用 14 件1996 年: 被引用 9 件1997 年: 被引用 17 件1998 年: 被引用 9 件1999 年: 被引用 9 件2000 年: 被引用 9 件2001 年: 被引用 17 件2002 年: 被引用 12 件2003 年: 被引用 9 件2004 年: 被引用 16 件2005 年: 被引用 11 件2006 年: 被引用 32 件2007 年: 被引用 14 件2008 年: 被引用 35 件2009 年: 被引用 62 件2010 年: 被引用 83 件2011 年: 被引用 78 件2012 年: 被引用 85 件2013 年: 被引用 98 件2014 年: 被引用 153 件2015 年: 被引用 132 件2016 年: 被引用 145 件2017 年: 被引用 299 件2018 年: 被引用 295 件2019 年: 被引用 1,239 件2020 年: 被引用 1,630 件2021 年: 被引用 1,808 件2022 年: 被引用 1,522 件2023 年: 被引用 1,014 件2024 年: 被引用 1,715 件2025 年: 被引用 773 件2026 年: 被引用 19 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,790 件、この内訳の 22.4%中国: 引用元論文 1,409 件、この内訳の 11.3%イタリア: 引用元論文 885 件、この内訳の 7.1%ドイツ: 引用元論文 657 件、この内訳の 5.3%イギリス: 引用元論文 599 件、この内訳の 4.8%フランス: 引用元論文 561 件、この内訳の 4.5%日本: 引用元論文 556 件、この内訳の 4.5%カナダ: 引用元論文 384 件、この内訳の 3.1%スペイン: 引用元論文 381 件、この内訳の 3.1%オランダ: 引用元論文 361 件、この内訳の 2.9%オーストラリア: 引用元論文 311 件、この内訳の 2.5%ベルギー: 引用元論文 261 件、この内訳の 2.1%
0%22.4%その他 26.4%

分野

  • Medicine77.5%
  • Biochemistry, Genetics and Molecular Biology14.4%
  • Immunology and Microbiology3.7%
  • Health Professions0.8%
  • Engineering0.7%
  • Dentistry0.5%
  • その他2.4%

トピック

  • Cancer Immunotherapy and Biomarkers10.2%
  • Head and Neck Cancer Studies9.8%
  • Immunotherapy and Immune Responses2.7%
  • Lung Cancer Treatments and Mutations2.4%
  • Thyroid Cancer Diagnosis and Treatment2.3%
  • Salivary Gland Tumors Diagnosis and Treatment2.3%
  • その他70.3%

共著者

全論文

検索で開く
  1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi ほか 119 名 - The Lancet 2019 被引用: 3,211

  2. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    著者: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 5,078

  3. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesco Caponigro, Ana Castro, Terrence P. Cescon, Kelvin Chan, Arvind Chaudhry, Bruno Chauffert, Ezra E.W. Cohen, Tibor Csőszi, Jan Paul de Boer, Jean‐Pierre Delord, Andreas Dietz, José Dinis, Charlotte Dupuis, Laurence Digue, József Erfán, Yolanda Escobar Alvarez, Mererid Evans, Mary J. Fidler, Martin Förster, Signe Friesland, Apar Kishor Ganti, Lionnel Geoffrois, Clíona Grant, Viktor Gruenwald, Kevin J. Harrington, Thomas K. Hoffmann, Geza Horvai, Arturas Inčiūra, Raymond Woo-Jun Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juárez Ramiro, Bogusława Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung‐Bae Kim, Judit Kocsis, Nuria Kotecki, Mark Kozloff, J. Lambea, László Landherr, Yuri Lantsukhay, Sergey Lazarev, Lip Way Lee, Christophe Le Tourneau, Lisa Licitra, Igor Lifirenko, Nicolas Mach, Danko Martincic, О. В. Маторин, Margaret McGrath, Jean‐Pascal Machiels, Ranee Mehra, Krzysztof Misiukiewicz, John C. Morris, Ф. Ф. Муфазалов, Jiaxin Niu, Devraj Srinivasan, Pedro Pérez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina P. Rodriguez, Frédéric Rolland, Antonio Russo, Ágnes Ruzsa, Frederico Sanches, Sangwon Shin, Mikhail Shtiveland ほか 13 名 - The Lancet 2018 被引用: 1,697

  4. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: , , , , , - Annals of Oncology 2020 被引用: 865

  5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

    著者: , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2019 被引用: 738

  6. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

    著者: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 365

  7. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

    著者: , , , , , , , , , , , , , , , , , , , , - Oral Oncology 2018 被引用: 800

  8. Rare cancers are not so rare: The rare cancer burden in Europe

    著者: , , , , , , , , , , , - European Journal of Cancer 2011 被引用: 785

  9. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    著者: , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 424

  10. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Margaret McGrath, Richard Greil, Dietmar Thurnher, Thorsten Fuereder, Martin Burian, Sylvie Rottey, Jean‐Pascal Machiels, Paul Clement, Stéphanie Henry, S. Deheneffe, Gustavo Vasconcelos Alves, Iane Pinto Figueiredo Lima, Josiane Mourão Dias, Pedro Rafael Martins De Marchi, Milena Perez Mak, Andrea Juliana Gomes, Dalvaro Oliveira de Castro Junior, Tatiane Cardoso Motta, Mônica Luciana Agostinho Padoan, Ana Paula Victorina, Sérgio Jobim Azevedo, Lillian L. Siu, Stephanie Yasmin Brule, John Hilton, Chang Shu Wang, Nathaniel Bouganim, Marc Webster, John Walker, Neil Chua, Ángela R. Zambrano, Alicia Quiroga Echeverri, Oscar Mauricio Niño Gomez, Carlos Alberto Ortiz, Luis Alejandro Rojas, Andrés Cardona Zorilla, Olga Marcela Urrego Meléndez, Petra Holečková, Bohuslav Melichar, Jakub Cvek, Jana Prausová, Milan Vošmik, Jean‐Pierre Delord, Xavier Zasadny, Lionnel Geoffrois, Yungan Tao, Y. Pointreau, Rainer Fietkau, Marlen Haderlein, Andreas Müller, Ursula C. Schroeder, Barbara Wollenberg, Simon Laban, Philipp Ivanyi, Viktor Gruenwald, Philippe Schafhausen, Orit Gutfeld, Iris Gluck, Aron Popovtzer, Amichay Meirovitz, Salem Billan, Baruch Brenner, Aron Popovtzer, Dror Limon, Lisa Licitra, Francesco Perri, Francesco Caponigro, Martina Violati, Daris Ferrari, Franco Nolè, Federica Bertolini ほか 90 名 - The Lancet Oncology 2024 被引用: 210

  11. Cabozantinib in Progressive Medullary Thyroid Cancer

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2013 被引用: 1,215

  12. Management of Salivary Gland Malignancy: ASCO Guideline

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 405

  13. Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 196

  14. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zoltán Takácsi Nagy, Ju‐Whei Lee, Catherine Fortpied, Jonathan Harris, Jean Bourhis, Anne Aupérin, Pierre Blanchard, Jean‐Pierre Pignon, David J. Adelstein, M. Alfonsi, Y. Belkacemi, Voichita Bar‐Ad, J. Bernier, Åse Bratland, G. Calais, Brittany Campbell, Jimmy J. Caudell, Sylvie Chabaud, Emmanuel Chamorey, Devendra Chaukar, Kwang Nam Choi, Olivier Choussy, Laurence Collette, Judith Cruz, Carla Dani, Etienne Dauzier, Arlene A. Forastiere, P. Garaud, V. Grégoire, A. Hackshaw, E. Haddad, Bruce G. Haffty, Aaron R. Hansen, Stefanie Hayoz, Jean-Claude Horiot, Branislav Jeremić, Theodore Karrison, Johannes A. Langendijk, M. Lapeyre, Éric Lartigau, Traci Leong, Quynh‐Thu Le, Patricia Lee, Freddi Lewin, Aihua Lin, Alberto Lopes, Samir Mehta, James Moon, Elizabeth Moyal, Bob‐Valéry Occéan, P. Olmi, Roberto Orecchia, Brian O’Sullivan, Jens Overgaard, Claire Petit, Harvey Quon, Giuseppe Sanguineti, Tuvana Satar, John Simes, Christian Simon, Clément Sire, S. Staar, C. Stromberger, P. Strojan, Stéphane Temam, David Thomson, A. Timochenko, Valter Torri, Vassilikì Tseroni, Jan B. Vermorken ほか 5 名 - Radiotherapy and Oncology 2021 被引用: 376

  15. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susana Puig, Frank Seebach, Gavin Thurston, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Timothy G. Bowler, Matthew G. Fury - The Lancet Oncology 2021 被引用: 278

  16. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc Maynadié, Anne‐Sophie Woronoff, Michel Robaszkiewicz, Isabelle Baldi, Alain Monnereau, Brigitte Trétarre, Nadine Bossard, Aurélien Belot, Marc Colonna, Florence Molinié, S. Bara, Claire Schvartz, B. Lapôtre‐Ledoux, Pascale Grosclaude, M. Meyer, Roland Stabenow, Sabine Luttmann, Andrea Eberle, Hermann Brenner, Alice Nennecke, Jutta Engel, G. Schubert-Fritschle, Joachim Kieschke, Jan Heidrich, Bernd Holleczek, Alexander Katalinic, Jón G. Jónasson, Laufey Tryggvadóttír, Harry Comber, Guido Mazzoleni, A. Bulatko, Carlotta Buzzoni, Adriano Giacomin, A. Mazzei A. Sutera Sardo, Stefano Ferretti, Emanuele Crocetti, Gianfranco Manneschi, Gemma Gatta, Milena Sant, H. Amash, C. Amati, Paolo Baili, Franco Berrino, S. Bonfarnuzzo, Laura Botta, F. Di Salvo, Roberto Foschi, C. Margutti, E. Meneghini, Pamela Minicozzi, Annalisa Trama, Diego Serraino, Antonella Zucchetto, Roberta De Angelis, M. Caldora, Riccardo Capocaccia, E. Carrani, Silvia Francisci, Sandra Mallone, Daniela Pierannunzio, P. Roazzi, Silvia Rossi, Mariano Santaquilani, Andrea Tavilla, Fabio Pannozzo, M. Natali, L Bonelli, Marina Vercelli, Valerio Gennaro, Paolo Ricci ほか 103 名 - European Journal of Cancer 2015 被引用: 485

  17. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 121

  18. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 被引用: 430

  19. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

    著者: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2017 被引用: 239

  20. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

    著者: , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2017 被引用: 284

  21. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2021 被引用: 107

  22. European Head and Neck Society recommendations for head and neck cancer survivorship care

    著者: , , , , , , , , , , , , - Oral Oncology 2022 被引用: 84

  23. 854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 32

  24. Major and minor salivary gland tumors

    著者: , , , , , - Critical Reviews in Oncology/Hematology 2009 被引用: 577